This update was originally posted by MassBio CEO & President Kendalle Burlin O’Connell on LinkedIn.
Congress is in the middle of a two-week recess, leaving Washington unusually quiet from a biotech perspective, at least on the surface. The policy environment for biotech continues to move, with a significant tariff announcement expected as early as today. MassBio is using this window to prepare for continued engagement on our priorities when members return and to monitor developments coming out of the Administration. Here’s what we’re watching:
Section 232 Pharma Tariff Announcement Expected: Details are still emerging, but the Trump administration is expected to announce 100% tariffs on imports of patented drugs and active pharmaceutical ingredients as soon as today, targeting companies that have not entered pricing agreements with the White House. The tariffs stem from a Section 232 national security investigation and are designed to pressure holdouts into the administration’s Most Favored Nation pricing initiative. While many large pharma companies have already struck deals, the implications for smaller biotech manufacturers, and for drug supply chains more broadly, remain deeply uncertain. We’ll be watching closely as details emerge.
Reconciliation Momentum and Drug Pricing Codification: There is growing momentum for a reconciliation package in the coming months. MFN codification efforts remain a real risk as Republicans look for revenue offsets and to address President Trumps’ repeated calls for legislation. Hearings on drug pricing are likely to pick up as reconciliation negotiations heat up. MassBio will continue making the case that pricing policies that undermine returns on innovation ultimately harm patients and the broader U.S. innovation ecosystem, not just companies.
Senate Small Business Committee Takes Bioeconomy on the Road: On April 7, the Senate Small Business Committee will hold a field hearing in Indiana titled “Fueling Innovation: The Role of Small Businesses in America’s Bioeconomy.” The hearing will bring together several founders, accelerator leaders, and regional innovation ecosystem builders to discuss how small biotech and life sciences companies are driving economic growth outside major hubs. While the location and witnesses may lend themselves to Midwest-specific discussions, the hearing reflects broader congressional interest in strengthening the small business innovation pipeline, so we’ll be watching for anything that may impact the Massachusetts early-stage biotech community.
FY27 Budget Request Expected This Week: The White House is expected to release its fiscal year 2027 budget request this week, and early reports suggest it will again propose cuts to the National Institutes of Health. The NIH received $48.7 billion in FY26, a modest increase over the prior year and a rejection of the President’s 40% proposed cut. Sen. Dave McCormick (R-PA), appearing alongside NIH Director Jay Bhattacharya in Philadelphia this week, said he would be “a strong advocate of maintaining and increasing NIH funding” and predicted that “many people in Congress will continue to support keeping NIH funding where it is or even growing.” Broad bipartisan resistance is what stopped last year’s cuts from becoming law, and the same dynamic is likely to play out again. Still, any reduction would represent a significant blow to the basic and translational research pipeline that Massachusetts biotech depends on. MassBio will be reviewing the full request and engaging appropriators as the FY27 process gets underway.